Insmed Incorporated INSM

Company Overview

Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, particularly in pulmonary and inflammatory conditions. The company operates within the biotechnology and specialty pharmaceutical industries, with its commercial and clinical activities centered on unmet medical needs in orphan and chronic diseases. Insmed’s primary revenue driver is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibiotic approved in multiple jurisdictions for treatment-refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen. In addition to its commercial portfolio, the company maintains a clinical-stage pipeline focused on respiratory and inflammatory diseases.

The company was founded in 1988 and evolved from earlier work in metabolic and endocrine therapies into a rare-disease-focused biotechnology company. Over time, Insmed shifted its strategic emphasis toward pulmonary medicine and inhaled therapeutics, leveraging proprietary delivery technologies and orphan-drug development pathways. Its positioning is supported by expertise in respiratory drug delivery, targeted rare-disease commercialization, and a focused specialty-care infrastructure serving pulmonologists and specialty treatment centers.